Skip to main content
Erschienen in: Seminars in Immunopathology 6/2019

08.11.2019 | Review

Resolution of allergic asthma

verfasst von: Susetta Finotto

Erschienen in: Seminars in Immunopathology | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Allergic asthma is an inflammatory disease of the airways characterized by recurrent episodes of wheezing and bronchoconstriction. Chronic inflammation may finally lead to structural damage followed by airway remodeling. Various studies in recent years contributed to unravel important aspects of the immunopathogenesis of asthma and adapted new pharmaceutical developments. Here, I consider some novel insights into the immunopathogenesis of asthma and the protective and pathogenic roles of some innate and adaptive immune cells as well as the function of soluble mediators such as cytokines. Particular attention will be given to new concepts on resolution of chronic airway inflammation for prevention of airway structural damage.
Literatur
1.
Zurück zum Zitat Hartert TV, Peebles RS Jr (2000) Epidemiology of asthma: the year in review. Curr Opin Pulm Med 6(1):4–9PubMed Hartert TV, Peebles RS Jr (2000) Epidemiology of asthma: the year in review. Curr Opin Pulm Med 6(1):4–9PubMed
2.
Zurück zum Zitat Xepapadaki P, Bachert C, Finotto S, Jartti T, Konstantinou GN, Kiefer A, Kowalski M, Lewandowska-Polak A, Lukkarinen H, Roumpedaki E, Sobanska A, Sintobin I, Vuorinen T, Zhang N, Zimmermann T, Papadopoulos NG (2018) Contribution of repeated infections in asthma persistence from preschool to school age: design and characteristics of the PreDicta cohort. Pediatr Allergy Immunol 29(4):383–393PubMed Xepapadaki P, Bachert C, Finotto S, Jartti T, Konstantinou GN, Kiefer A, Kowalski M, Lewandowska-Polak A, Lukkarinen H, Roumpedaki E, Sobanska A, Sintobin I, Vuorinen T, Zhang N, Zimmermann T, Papadopoulos NG (2018) Contribution of repeated infections in asthma persistence from preschool to school age: design and characteristics of the PreDicta cohort. Pediatr Allergy Immunol 29(4):383–393PubMed
3.
Zurück zum Zitat Megremis S, Niespodziana K, Cabauatan C, Xepapadaki P, Kowalski ML, Jartti T, Bachert C, Finotto S, West P, Stamataki S, Lewandowska-Polak A, Lukkarinen H, Zhang N, Zimmermann T, Stolz F, Neubauer A, Akdis M, Andreakos E, Valenta R, Papadopoulos NG (2018) Rhinovirus species-specific antibodies differentially reflect clinical outcomes in health and asthma. Am J Respir Crit Care Med Megremis S, Niespodziana K, Cabauatan C, Xepapadaki P, Kowalski ML, Jartti T, Bachert C, Finotto S, West P, Stamataki S, Lewandowska-Polak A, Lukkarinen H, Zhang N, Zimmermann T, Stolz F, Neubauer A, Akdis M, Andreakos E, Valenta R, Papadopoulos NG (2018) Rhinovirus species-specific antibodies differentially reflect clinical outcomes in health and asthma. Am J Respir Crit Care Med
4.
Zurück zum Zitat Earl CS, An SQ, Ryan RP (2015) The changing face of asthma and its relation with microbes. Trends Microbiol 23(7):408–418PubMedCentral Earl CS, An SQ, Ryan RP (2015) The changing face of asthma and its relation with microbes. Trends Microbiol 23(7):408–418PubMedCentral
5.
Zurück zum Zitat Strunk RC, Bloomberg GR (2006) Omalizumab for asthma. N Engl J Med 354(25):2689–2695PubMed Strunk RC, Bloomberg GR (2006) Omalizumab for asthma. N Engl J Med 354(25):2689–2695PubMed
6.
Zurück zum Zitat Chen Q, Guo X, Deng N, Liu L, Chen S, Wang A, Li R, Huang Y, Ding X, Yu H, Hu S, Nie H (2019) alpha-galactosylceramide treatment before allergen sensitization promotes iNKT cell-mediated induction of Treg cells, preventing Th2 cell responses in murine asthma. J Biol Chem 294(14):5438–5455 Chen Q, Guo X, Deng N, Liu L, Chen S, Wang A, Li R, Huang Y, Ding X, Yu H, Hu S, Nie H (2019) alpha-galactosylceramide treatment before allergen sensitization promotes iNKT cell-mediated induction of Treg cells, preventing Th2 cell responses in murine asthma. J Biol Chem 294(14):5438–5455
7.
Zurück zum Zitat Chia YL, Yan L, Yu B, Wang B, Barker P, Goldman M, Roskos L (2019) Relationship Between benralizumab exposure and efficacy for patients with severe eosinophilic asthma. Clin Pharmacol Ther 106(2):383–390PubMedPubMedCentral Chia YL, Yan L, Yu B, Wang B, Barker P, Goldman M, Roskos L (2019) Relationship Between benralizumab exposure and efficacy for patients with severe eosinophilic asthma. Clin Pharmacol Ther 106(2):383–390PubMedPubMedCentral
8.
9.
Zurück zum Zitat Fishe JN, Palmer E, Finlay E, Smotherman C, Gautam S, Hendry P, Hendeles L (2019) A statewide study of the epidemiology of emergency medical services’ management of pediatric asthma. Pediatr Emerg Care Fishe JN, Palmer E, Finlay E, Smotherman C, Gautam S, Hendry P, Hendeles L (2019) A statewide study of the epidemiology of emergency medical services’ management of pediatric asthma. Pediatr Emerg Care
10.
Zurück zum Zitat Morgan BW, Grigsby MR, Siddharthan T, Chowdhury M, Rubinstein A, Gutierrez L, Irazola V, Miranda JJ, Bernabe-Ortiz A, Alam D, Wise RA, Checkley W (2019) Epidemiology and risk factors of asthma-chronic obstructive pulmonary disease overlap in low- and middle-income countries. J Allergy Clin Immunol 143(4):1598–1606PubMed Morgan BW, Grigsby MR, Siddharthan T, Chowdhury M, Rubinstein A, Gutierrez L, Irazola V, Miranda JJ, Bernabe-Ortiz A, Alam D, Wise RA, Checkley W (2019) Epidemiology and risk factors of asthma-chronic obstructive pulmonary disease overlap in low- and middle-income countries. J Allergy Clin Immunol 143(4):1598–1606PubMed
11.
Zurück zum Zitat Sordillo JE, Kelly R, Bunyavanich S, McGeachie M, Qiu W, Croteau-Chonka DC, Soto-Quiros M, Avila L, Celedon JC, Brehm JM, Weiss ST, Gold DR, Litonjua AA (2015) Genome-wide expression profiles identify potential targets for gene-environment interactions in asthma severity. J Allergy Clin Immunol 136(4):885–92 e2PubMedPubMedCentral Sordillo JE, Kelly R, Bunyavanich S, McGeachie M, Qiu W, Croteau-Chonka DC, Soto-Quiros M, Avila L, Celedon JC, Brehm JM, Weiss ST, Gold DR, Litonjua AA (2015) Genome-wide expression profiles identify potential targets for gene-environment interactions in asthma severity. J Allergy Clin Immunol 136(4):885–92 e2PubMedPubMedCentral
12.
Zurück zum Zitat Holgate ST (2012) Innate and adaptive immune responses in asthma. Nat Med 18(5):673–683PubMed Holgate ST (2012) Innate and adaptive immune responses in asthma. Nat Med 18(5):673–683PubMed
13.
Zurück zum Zitat Lambrecht BN, Hammad H, Fahy JV (2019) The cytokines of asthma. Immunity 50(4):975–991PubMed Lambrecht BN, Hammad H, Fahy JV (2019) The cytokines of asthma. Immunity 50(4):975–991PubMed
14.
Zurück zum Zitat Alagha K, Bourdin A, Vernisse C, Garulli C, Tummino C, Charriot J, Vachier I, Suehs C, Chanez P, Gras D (2019) Goblet cell hyperplasia as a feature of neutrophilic asthma. Clin Exp Allergy 49(6):781–788PubMed Alagha K, Bourdin A, Vernisse C, Garulli C, Tummino C, Charriot J, Vachier I, Suehs C, Chanez P, Gras D (2019) Goblet cell hyperplasia as a feature of neutrophilic asthma. Clin Exp Allergy 49(6):781–788PubMed
15.
Zurück zum Zitat Bullone M, Carriero V, Bertolini F, Folino A, Mannelli A, Di Stefano A, Gnemmi I, Torchio R, Ricciardolo FLM (2019) Elevated serum IgE, OCS-dependence and IL-17/22 expression in highly neutrophilic asthma. Eur Respir J Bullone M, Carriero V, Bertolini F, Folino A, Mannelli A, Di Stefano A, Gnemmi I, Torchio R, Ricciardolo FLM (2019) Elevated serum IgE, OCS-dependence and IL-17/22 expression in highly neutrophilic asthma. Eur Respir J
16.
Zurück zum Zitat Kalchiem-Dekel O, Yao X, Levine SJ (2019) Meeting the challenge of identifying new treatments for type 2-low neutrophilic asthma. Chest Kalchiem-Dekel O, Yao X, Levine SJ (2019) Meeting the challenge of identifying new treatments for type 2-low neutrophilic asthma. Chest
17.
Zurück zum Zitat Ravi A, Chowdhury S, Dijkhuis A, Bonta PI, Sterk PJ, Lutter R (2019) Neutrophilic inflammation in asthma and defective epithelial translational control. Eur Respir J 54(2)PubMed Ravi A, Chowdhury S, Dijkhuis A, Bonta PI, Sterk PJ, Lutter R (2019) Neutrophilic inflammation in asthma and defective epithelial translational control. Eur Respir J 54(2)PubMed
18.
Zurück zum Zitat Clark KL, Li Y, Krauss MR, Kelley PW (2000) The asthma accession standard: a survival analysis of military recruits, 1995 to 1997. Mil Med 165(11):852–854PubMed Clark KL, Li Y, Krauss MR, Kelley PW (2000) The asthma accession standard: a survival analysis of military recruits, 1995 to 1997. Mil Med 165(11):852–854PubMed
19.
Zurück zum Zitat Liu H, Tan J, Liu J, Feng H, Pan D (2019) Altered mast cell activity in response to rhinovirus infection provides novel insight into asthma. J Asthma 18:1–9 Liu H, Tan J, Liu J, Feng H, Pan D (2019) Altered mast cell activity in response to rhinovirus infection provides novel insight into asthma. J Asthma 18:1–9
20.
Zurück zum Zitat Salomonsson M, Malinovschi A, Kalm-Stephens P, Dahlin JS, Janson C, Alving K, Hallgren J (2019) Circulating mast cell progenitors correlate with reduced lung function in allergic asthma. Clin Exp Allergy 49(6):874–882PubMedPubMedCentral Salomonsson M, Malinovschi A, Kalm-Stephens P, Dahlin JS, Janson C, Alving K, Hallgren J (2019) Circulating mast cell progenitors correlate with reduced lung function in allergic asthma. Clin Exp Allergy 49(6):874–882PubMedPubMedCentral
21.
Zurück zum Zitat Komi DEA, Bjermer L (2019) Mast Cell-mediated orchestration of the immune responses in human allergic asthma: current insights. Clin Rev Allergy Immunol 56(2):234–247 Komi DEA, Bjermer L (2019) Mast Cell-mediated orchestration of the immune responses in human allergic asthma: current insights. Clin Rev Allergy Immunol 56(2):234–247
22.
Zurück zum Zitat Petsky HL, Cates CJ, Kew KM, Chang AB (2018) Tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils): a systematic review and meta-analysis. Thorax 73(12):1110–1119 Petsky HL, Cates CJ, Kew KM, Chang AB (2018) Tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils): a systematic review and meta-analysis. Thorax 73(12):1110–1119
23.
Zurück zum Zitat Cooper K, Frampton G, Harris P, Rose M, Chorozoglou M, Pickett K (2018) Reslizumab for Treating asthma with elevated blood eosinophils inadequately controlled by inhaled corticosteroids: an evidence review group perspective of a NICE single technology appraisal. pharmacoeconomics 36(5):545–553PubMed Cooper K, Frampton G, Harris P, Rose M, Chorozoglou M, Pickett K (2018) Reslizumab for Treating asthma with elevated blood eosinophils inadequately controlled by inhaled corticosteroids: an evidence review group perspective of a NICE single technology appraisal. pharmacoeconomics 36(5):545–553PubMed
24.
Zurück zum Zitat Yoshikawa S, Oh-Hora M, Hashimoto R, Nagao T, Peters L, Egawa M, Ohta T, Miyake K, Adachi T, Kawano Y, Yamanishi Y, Karasuyama H (2019) Pivotal role of STIM2, but not STIM1, in IL-4 production by IL-3-stimulated murine basophils. Sci Signal 12(576)PubMed Yoshikawa S, Oh-Hora M, Hashimoto R, Nagao T, Peters L, Egawa M, Ohta T, Miyake K, Adachi T, Kawano Y, Yamanishi Y, Karasuyama H (2019) Pivotal role of STIM2, but not STIM1, in IL-4 production by IL-3-stimulated murine basophils. Sci Signal 12(576)PubMed
25.
Zurück zum Zitat Cirino M, Lagente V, Lefort J, Vargaftig BB (1986) A study with BN 52021 demonstrates the involvement of PAF-acether in IgE-dependent anaphylactic bronchoconstriction. Prostaglandins 32(1):121–126PubMed Cirino M, Lagente V, Lefort J, Vargaftig BB (1986) A study with BN 52021 demonstrates the involvement of PAF-acether in IgE-dependent anaphylactic bronchoconstriction. Prostaglandins 32(1):121–126PubMed
26.
Zurück zum Zitat Casale TB, Luskin AT, Busse W, Zeiger RS, Trzaskoma B, Yang M, Griffin NM, Chipps BE (2019) Omalizumab Effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study. J Allergy Clin Immunol Pract 7(1):156–164 e1PubMed Casale TB, Luskin AT, Busse W, Zeiger RS, Trzaskoma B, Yang M, Griffin NM, Chipps BE (2019) Omalizumab Effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study. J Allergy Clin Immunol Pract 7(1):156–164 e1PubMed
27.
Zurück zum Zitat Matucci A, Vultaggio A, Maggi E, Kasujee I (2018) Is IgE or eosinophils the key player in allergic asthma pathogenesis? Are we asking the right question? Respir Res 19(1):113PubMedCentral Matucci A, Vultaggio A, Maggi E, Kasujee I (2018) Is IgE or eosinophils the key player in allergic asthma pathogenesis? Are we asking the right question? Respir Res 19(1):113PubMedCentral
28.
Zurück zum Zitat Rosenberg HF, Dyer KD, Foster PS (2013) Eosinophils: changing perspectives in health and disease. Nat Rev Immunol 13(1):9–22PubMed Rosenberg HF, Dyer KD, Foster PS (2013) Eosinophils: changing perspectives in health and disease. Nat Rev Immunol 13(1):9–22PubMed
29.
Zurück zum Zitat Mesnil C, Raulier S, Paulissen G, Xiao X, Birrell MA, Pirottin D, Janss T, Starkl P, Ramery E, Henket M, Schleich FN, Radermecker M, Thielemans K, Gillet L, Thiry M, Belvisi MG, Louis R, Desmet C, Marichal T, Bureau F (2016) Lung-resident eosinophils represent a distinct regulatory eosinophil subset. J Clin Invest 126(9):3279–3295PubMedPubMedCentral Mesnil C, Raulier S, Paulissen G, Xiao X, Birrell MA, Pirottin D, Janss T, Starkl P, Ramery E, Henket M, Schleich FN, Radermecker M, Thielemans K, Gillet L, Thiry M, Belvisi MG, Louis R, Desmet C, Marichal T, Bureau F (2016) Lung-resident eosinophils represent a distinct regulatory eosinophil subset. J Clin Invest 126(9):3279–3295PubMedPubMedCentral
30.
Zurück zum Zitat Kopf M, Brombacher F, Hodgkin PD, Ramsay AJ, Milbourne EA, Dai WJ, Ovington KS, Behm CA, Kohler G, Young IG, Matthaei KI (1996) IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. Immunity 4(1):15–24PubMed Kopf M, Brombacher F, Hodgkin PD, Ramsay AJ, Milbourne EA, Dai WJ, Ovington KS, Behm CA, Kohler G, Young IG, Matthaei KI (1996) IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. Immunity 4(1):15–24PubMed
31.
Zurück zum Zitat Radermecker C, Sabatel C, Vanwinge C, Ruscitti C, Marechal P, Perin F, Schyns J, Rocks N, Toussaint M, Cataldo D, Johnston SL, Bureau F, Marichal T (2019) Locally instructed CXCR4(hi) neutrophils trigger environment-driven allergic asthma through the release of neutrophil extracellular traps. Nat Immunol Radermecker C, Sabatel C, Vanwinge C, Ruscitti C, Marechal P, Perin F, Schyns J, Rocks N, Toussaint M, Cataldo D, Johnston SL, Bureau F, Marichal T (2019) Locally instructed CXCR4(hi) neutrophils trigger environment-driven allergic asthma through the release of neutrophil extracellular traps. Nat Immunol
32.
Zurück zum Zitat Ekstedt S, Stenberg H, Tufvesson E, Diamant Z, Bjermer L, Kumlien Georen S, Cardell LO (2019) The potential role of CD16(high) CD62L(dim) neutrophils in the allergic asthma. Allergy Ekstedt S, Stenberg H, Tufvesson E, Diamant Z, Bjermer L, Kumlien Georen S, Cardell LO (2019) The potential role of CD16(high) CD62L(dim) neutrophils in the allergic asthma. Allergy
33.
Zurück zum Zitat Busse WW (2019) What are those neutrophils doing in severe asthma anyway? J Allergy Clin Immunol Pract 7(2):526–528PubMed Busse WW (2019) What are those neutrophils doing in severe asthma anyway? J Allergy Clin Immunol Pract 7(2):526–528PubMed
34.
Zurück zum Zitat Grunwell JR, Stephenson ST, Tirouvanziam R, Brown LAS, Brown MR, Fitzpatrick AM (2019) Children with neutrophil-predominant severe asthma have proinflammatory neutrophils with enhanced survival and impaired clearance. J Allergy Clin Immunol Pract 7(2):516–525 e6PubMed Grunwell JR, Stephenson ST, Tirouvanziam R, Brown LAS, Brown MR, Fitzpatrick AM (2019) Children with neutrophil-predominant severe asthma have proinflammatory neutrophils with enhanced survival and impaired clearance. J Allergy Clin Immunol Pract 7(2):516–525 e6PubMed
35.
Zurück zum Zitat Radermecker C, Louis R, Bureau F, Marichal T (2018) Role of neutrophils in allergic asthma. Curr Opin Immunol 54:28–34PubMed Radermecker C, Louis R, Bureau F, Marichal T (2018) Role of neutrophils in allergic asthma. Curr Opin Immunol 54:28–34PubMed
36.
Zurück zum Zitat Saradna A, Do DC, Kumar S, Fu QL, Gao P (2018) Macrophage polarization and allergic asthma. Transl Res 191:1–14PubMed Saradna A, Do DC, Kumar S, Fu QL, Gao P (2018) Macrophage polarization and allergic asthma. Transl Res 191:1–14PubMed
37.
Zurück zum Zitat Chung FT, Huang HY, Lo CY, Huang YC, Lin CW, He CC, He JR, Sheng TF, Wang CH (2019) Increased ratio of matrix metalloproteinase-9 (MMP-9)/Tissue inhibitor metalloproteinase-1 from alveolar macrophages in chronic asthma with a fast decline in FEV1 at 5-year follow-up. J Clin Med 8(9)PubMedCentral Chung FT, Huang HY, Lo CY, Huang YC, Lin CW, He CC, He JR, Sheng TF, Wang CH (2019) Increased ratio of matrix metalloproteinase-9 (MMP-9)/Tissue inhibitor metalloproteinase-1 from alveolar macrophages in chronic asthma with a fast decline in FEV1 at 5-year follow-up. J Clin Med 8(9)PubMedCentral
38.
Zurück zum Zitat Tokunaga Y, Imaoka H, Kaku Y, Kawayama T, Hoshino T (2019) The significance of CD163-expressing macrophages in asthma. Ann Allergy Asthma Immunol 123(3):263–270PubMed Tokunaga Y, Imaoka H, Kaku Y, Kawayama T, Hoshino T (2019) The significance of CD163-expressing macrophages in asthma. Ann Allergy Asthma Immunol 123(3):263–270PubMed
39.
Zurück zum Zitat de Groot LES, van der Veen TA, Martinez FO, Hamann J, Lutter R, Melgert BN (2019) Oxidative stress and macrophages: driving forces behind exacerbations of asthma and chronic obstructive pulmonary disease? Am J Physiol Lung Cell Mol Physiol 316(2):L369–L384PubMed de Groot LES, van der Veen TA, Martinez FO, Hamann J, Lutter R, Melgert BN (2019) Oxidative stress and macrophages: driving forces behind exacerbations of asthma and chronic obstructive pulmonary disease? Am J Physiol Lung Cell Mol Physiol 316(2):L369–L384PubMed
40.
Zurück zum Zitat Ubel C, Graser A, Koch S, Rieker RJ, Lehr HA, Muller M, Finotto S (2014) Role of Tyk-2 in Th9 and Th17 cells in allergic asthma. Sci Rep 4:5865PubMedPubMedCentral Ubel C, Graser A, Koch S, Rieker RJ, Lehr HA, Muller M, Finotto S (2014) Role of Tyk-2 in Th9 and Th17 cells in allergic asthma. Sci Rep 4:5865PubMedPubMedCentral
41.
Zurück zum Zitat Chen Z, Wang L (2019) Ovalbumin induces natural killer cells to secrete Th2 cytokines IL5 and IL13 in a mouse model of asthma. Mol Med Rep 19(4):3210–3216PubMedPubMedCentral Chen Z, Wang L (2019) Ovalbumin induces natural killer cells to secrete Th2 cytokines IL5 and IL13 in a mouse model of asthma. Mol Med Rep 19(4):3210–3216PubMedPubMedCentral
42.
Zurück zum Zitat Leomicronn B (2017) T cells in allergic asthma: key players beyond the Th2 pathway. Curr Allergy Asthma Rep 17(7):43PubMed Leomicronn B (2017) T cells in allergic asthma: key players beyond the Th2 pathway. Curr Allergy Asthma Rep 17(7):43PubMed
43.
Zurück zum Zitat Krabbendam L, Bal SM, Spits H, Golebski K (2018) New insights into the function, development, and plasticity of type 2 innate lymphoid cells. Immunol Rev 286(1):74–85PubMed Krabbendam L, Bal SM, Spits H, Golebski K (2018) New insights into the function, development, and plasticity of type 2 innate lymphoid cells. Immunol Rev 286(1):74–85PubMed
44.
Zurück zum Zitat Nakamura Y, Ghaffar O, Olivenstein R, Taha RA, Soussi-Gounni A, Zhang DH, Ray A, Hamid Q (1999) Gene expression of the GATA-3 transcription factor is increased in atopic asthma. J Allergy Clin Immunol 103(2 Pt 1):215–222PubMed Nakamura Y, Ghaffar O, Olivenstein R, Taha RA, Soussi-Gounni A, Zhang DH, Ray A, Hamid Q (1999) Gene expression of the GATA-3 transcription factor is increased in atopic asthma. J Allergy Clin Immunol 103(2 Pt 1):215–222PubMed
45.
Zurück zum Zitat Finotto S, De Sanctis GT, Lehr HA, Herz U, Buerke M, Schipp M, Bartsch B, Atreya R, Schmitt E, Galle PR, Renz H, Neurath MF (2001) Treatment of allergic airway inflammation and hyperresponsiveness by antisense-induced local blockade of GATA-3 expression. J Exp Med 193(11):1247–1260PubMedPubMedCentral Finotto S, De Sanctis GT, Lehr HA, Herz U, Buerke M, Schipp M, Bartsch B, Atreya R, Schmitt E, Galle PR, Renz H, Neurath MF (2001) Treatment of allergic airway inflammation and hyperresponsiveness by antisense-induced local blockade of GATA-3 expression. J Exp Med 193(11):1247–1260PubMedPubMedCentral
46.
Zurück zum Zitat Krug N, Hohlfeld JM, Kirsten AM, Kornmann O, Beeh KM, Kappeler D, Korn S, Ignatenko S, Timmer W, Rogon C, Zeitvogel J, Zhang N, Bille J, Homburg U, Turowska A, Bachert C, Werfel T, Buhl R, Renz J, Garn H, Renz H (2015) Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme. N Engl J Med 372(21):1987–1995PubMed Krug N, Hohlfeld JM, Kirsten AM, Kornmann O, Beeh KM, Kappeler D, Korn S, Ignatenko S, Timmer W, Rogon C, Zeitvogel J, Zhang N, Bille J, Homburg U, Turowska A, Bachert C, Werfel T, Buhl R, Renz J, Garn H, Renz H (2015) Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme. N Engl J Med 372(21):1987–1995PubMed
47.
Zurück zum Zitat Ubel C, Sopel N, Graser A, Hildner K, Reinhardt C, Zimmermann T, Rieker RJ, Maier A, Neurath MF, Murphy KM, Finotto S (2014) The activating protein 1 transcription factor basic leucine zipper transcription factor, ATF-like (BATF), regulates lymphocyte- and mast cell-driven immune responses in the setting of allergic asthma. J Allergy Clin Immunol 133(1):198–206 e1-9PubMed Ubel C, Sopel N, Graser A, Hildner K, Reinhardt C, Zimmermann T, Rieker RJ, Maier A, Neurath MF, Murphy KM, Finotto S (2014) The activating protein 1 transcription factor basic leucine zipper transcription factor, ATF-like (BATF), regulates lymphocyte- and mast cell-driven immune responses in the setting of allergic asthma. J Allergy Clin Immunol 133(1):198–206 e1-9PubMed
48.
Zurück zum Zitat Jabeen R, Goswami R, Awe O, Kulkarni A, Nguyen ET, Attenasio A, Walsh D, Olson MR, Kim MH, Tepper RS, Sun J, Kim CH, Taparowsky EJ, Zhou B, Kaplan MH (2013) Th9 cell development requires a BATF-regulated transcriptional network. J Clin Invest 123(11):4641–4653PubMedCentral Jabeen R, Goswami R, Awe O, Kulkarni A, Nguyen ET, Attenasio A, Walsh D, Olson MR, Kim MH, Tepper RS, Sun J, Kim CH, Taparowsky EJ, Zhou B, Kaplan MH (2013) Th9 cell development requires a BATF-regulated transcriptional network. J Clin Invest 123(11):4641–4653PubMedCentral
49.
Zurück zum Zitat Jabeen R, Kaplan MH (2012) The symphony of the ninth: the development and function of Th9 cells. Curr Opin Immunol 24(3):303–307PubMedPubMedCentral Jabeen R, Kaplan MH (2012) The symphony of the ninth: the development and function of Th9 cells. Curr Opin Immunol 24(3):303–307PubMedPubMedCentral
51.
Zurück zum Zitat Liao W, Spolski R, Li P, Du N, West EE, Ren M, Mitra S, Leonard WJ (2014) Opposing actions of IL-2 and IL-21 on Th9 differentiation correlate with their differential regulation of BCL6 expression. Proc Natl Acad Sci U S A 111(9):3508–3513PubMedPubMedCentral Liao W, Spolski R, Li P, Du N, West EE, Ren M, Mitra S, Leonard WJ (2014) Opposing actions of IL-2 and IL-21 on Th9 differentiation correlate with their differential regulation of BCL6 expression. Proc Natl Acad Sci U S A 111(9):3508–3513PubMedPubMedCentral
52.
Zurück zum Zitat Licona-Limon P, Henao-Mejia J, Temann AU, Gagliani N, Licona-Limon I, Ishigame H, Hao L, Herbert DR, Flavell RA (2013) Th9 cells drive host immunity against gastrointestinal worm infection. Immunity 39(4):744–757PubMed Licona-Limon P, Henao-Mejia J, Temann AU, Gagliani N, Licona-Limon I, Ishigame H, Hao L, Herbert DR, Flavell RA (2013) Th9 cells drive host immunity against gastrointestinal worm infection. Immunity 39(4):744–757PubMed
53.
Zurück zum Zitat Neurath MF, Kaplan MH (2017) Th9 cells in immunity and immunopathological diseases. Semin Immunopathol 39(1):1–4PubMed Neurath MF, Kaplan MH (2017) Th9 cells in immunity and immunopathological diseases. Semin Immunopathol 39(1):1–4PubMed
54.
Zurück zum Zitat Levitt RC, McLane MP, MacDonald D, Ferrante V, Weiss C, Zhou T, Holroyd KJ, Nicolaides NC (1999) IL-9 pathway in asthma: new therapeutic targets for allergic inflammatory disorders. J Allergy Clin Immunol 103(5 Pt 2):S485–S491PubMed Levitt RC, McLane MP, MacDonald D, Ferrante V, Weiss C, Zhou T, Holroyd KJ, Nicolaides NC (1999) IL-9 pathway in asthma: new therapeutic targets for allergic inflammatory disorders. J Allergy Clin Immunol 103(5 Pt 2):S485–S491PubMed
55.
Zurück zum Zitat Hoppenot D, Malakauskas K, Lavinskiene S, Sakalauskas R (2015) p-STAT6, PU.1, and NF-kappaB are involved in allergen-induced late-phase airway inflammation in asthma patients. BMC Pulm Med 15:122PubMedPubMedCentral Hoppenot D, Malakauskas K, Lavinskiene S, Sakalauskas R (2015) p-STAT6, PU.1, and NF-kappaB are involved in allergen-induced late-phase airway inflammation in asthma patients. BMC Pulm Med 15:122PubMedPubMedCentral
56.
Zurück zum Zitat Hoppenot D, Malakauskas K, Lavinskiene S, Bajoriuniene I, Kalinauskaite V, Sakalauskas R (2015) Peripheral blood Th9 cells and eosinophil apoptosis in asthma patients. Medicina 51(1):10–17PubMed Hoppenot D, Malakauskas K, Lavinskiene S, Bajoriuniene I, Kalinauskaite V, Sakalauskas R (2015) Peripheral blood Th9 cells and eosinophil apoptosis in asthma patients. Medicina 51(1):10–17PubMed
57.
Zurück zum Zitat Finotto S (2018) B lymphocyte-induced maturation protein 1 (Blimp-1), a negative regulator of TH9 development, orchestrates the resolution of airway inflammation in patients with allergic asthma. J Allergy Clin Immunol Finotto S (2018) B lymphocyte-induced maturation protein 1 (Blimp-1), a negative regulator of TH9 development, orchestrates the resolution of airway inflammation in patients with allergic asthma. J Allergy Clin Immunol
58.
Zurück zum Zitat Erpenbeck VJ, Hohlfeld JM, Volkmann B, Hagenberg A, Geldmacher H, Braun A, Krug N (2003) Segmental allergen challenge in patients with atopic asthma leads to increased IL-9 expression in bronchoalveolar lavage fluid lymphocytes. J Allergy Clin Immunol 111(6):1319–1327PubMed Erpenbeck VJ, Hohlfeld JM, Volkmann B, Hagenberg A, Geldmacher H, Braun A, Krug N (2003) Segmental allergen challenge in patients with atopic asthma leads to increased IL-9 expression in bronchoalveolar lavage fluid lymphocytes. J Allergy Clin Immunol 111(6):1319–1327PubMed
59.
Zurück zum Zitat Abdelilah S, Latifa K, Esra N, Cameron L, Bouchaib L, Nicolaides N, Levitt R, Hamid Q (2001) Functional expression of IL-9 receptor by human neutrophils from asthmatic donors: role in IL-8 release. J Immunol 166(4):2768–2774PubMed Abdelilah S, Latifa K, Esra N, Cameron L, Bouchaib L, Nicolaides N, Levitt R, Hamid Q (2001) Functional expression of IL-9 receptor by human neutrophils from asthmatic donors: role in IL-8 release. J Immunol 166(4):2768–2774PubMed
60.
Zurück zum Zitat Bhathena PR, Comhair SA, Holroyd KJ, Erzurum SC (2000) Interleukin-9 receptor expression in asthmatic airways In vivo. Lung 178(3):149–160PubMed Bhathena PR, Comhair SA, Holroyd KJ, Erzurum SC (2000) Interleukin-9 receptor expression in asthmatic airways In vivo. Lung 178(3):149–160PubMed
61.
Zurück zum Zitat Cheng G, Arima M, Honda K, Hirata H, Eda F, Yoshida N, Fukushima F, Ishii Y, Fukuda T (2002) Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model. Am J Respir Crit Care Med 166(3):409–416PubMed Cheng G, Arima M, Honda K, Hirata H, Eda F, Yoshida N, Fukushima F, Ishii Y, Fukuda T (2002) Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model. Am J Respir Crit Care Med 166(3):409–416PubMed
62.
Zurück zum Zitat Shimbara A, Christodoulopoulos P, Soussi-Gounni A, Olivenstein R, Nakamura Y, Levitt RC, Nicolaides NC, Holroyd KJ, Tsicopoulos A, Lafitte JJ, Wallaert B, Hamid QA (2000) IL-9 and its receptor in allergic and nonallergic lung disease: increased expression in asthma. J Allergy Clin Immunol 105(1 Pt 1):108–115PubMed Shimbara A, Christodoulopoulos P, Soussi-Gounni A, Olivenstein R, Nakamura Y, Levitt RC, Nicolaides NC, Holroyd KJ, Tsicopoulos A, Lafitte JJ, Wallaert B, Hamid QA (2000) IL-9 and its receptor in allergic and nonallergic lung disease: increased expression in asthma. J Allergy Clin Immunol 105(1 Pt 1):108–115PubMed
63.
Zurück zum Zitat Toda M, Tulic MK, Levitt RC, Hamid Q (2002) A calcium-activated chloride channel (HCLCA1) is strongly related to IL-9 expression and mucus production in bronchial epithelium of patients with asthma. J Allergy Clin Immunol 109(2):246–250PubMed Toda M, Tulic MK, Levitt RC, Hamid Q (2002) A calcium-activated chloride channel (HCLCA1) is strongly related to IL-9 expression and mucus production in bronchial epithelium of patients with asthma. J Allergy Clin Immunol 109(2):246–250PubMed
64.
Zurück zum Zitat Oh CK, Leigh R, McLaurin KK, Kim K, Hultquist M, Molfino NA (2013) A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma. Respir Res 14:93PubMedCentral Oh CK, Leigh R, McLaurin KK, Kim K, Hultquist M, Molfino NA (2013) A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma. Respir Res 14:93PubMedCentral
65.
Zurück zum Zitat Rubner FJ, Jackson DJ, Evans MD, Gangnon RE, Tisler CJ, Pappas TE, Gern JE, Lemanske RF Jr (2017) Early life rhinovirus wheezing, allergic sensitization, and asthma risk at adolescence. J Allergy Clin Immunol 139(2):501–507 Rubner FJ, Jackson DJ, Evans MD, Gangnon RE, Tisler CJ, Pappas TE, Gern JE, Lemanske RF Jr (2017) Early life rhinovirus wheezing, allergic sensitization, and asthma risk at adolescence. J Allergy Clin Immunol 139(2):501–507
66.
Zurück zum Zitat Bergauer A, Sopel N, Kross B, Vuorinen T, Xepapadaki P, Weiss ST, Blau A, Sharma H, Kraus C, Springel R, Rauh M, Mittler S, Graser A, Zimmermann T, Melichar VO, Kiefer A, Kowalski ML, Sobanska A, Jartti T, Lukkarinen H, Papadopoulos NG, Finotto S (2017) Rhinovirus species/genotypes and interferon-lambda: subtypes, receptor and polymorphisms - missing pieces of the puzzle of childhood asthma? Eur Respir J 49(3)PubMed Bergauer A, Sopel N, Kross B, Vuorinen T, Xepapadaki P, Weiss ST, Blau A, Sharma H, Kraus C, Springel R, Rauh M, Mittler S, Graser A, Zimmermann T, Melichar VO, Kiefer A, Kowalski ML, Sobanska A, Jartti T, Lukkarinen H, Papadopoulos NG, Finotto S (2017) Rhinovirus species/genotypes and interferon-lambda: subtypes, receptor and polymorphisms - missing pieces of the puzzle of childhood asthma? Eur Respir J 49(3)PubMed
67.
Zurück zum Zitat Hansel TT, Tunstall T, Trujillo-Torralbo MB, Shamji B, del-Rosario A, Dhariwal J, Kirk PDW, Stumpf MPH, Koopmann J, Telcian A, Aniscenko J, Gogsadze L, Bakhsoliani E, Stanciu L, Bartlett N, Edwards M, Walton R, Mallia P, Hunt TM, Hunt TL, Hunt DG, Westwick J, Edwards M, Kon OM, Jackson DJ, Johnston SL (2017) A Comprehensive evaluation of nasal and bronchial cytokines and chemokines following experimental rhinovirus infection in allergic asthma: increased interferons (IFN-gamma and IFN-lambda) and type 2 inflammation (IL-5 and IL-13). EBioMedicine 19:128–138PubMedCentral Hansel TT, Tunstall T, Trujillo-Torralbo MB, Shamji B, del-Rosario A, Dhariwal J, Kirk PDW, Stumpf MPH, Koopmann J, Telcian A, Aniscenko J, Gogsadze L, Bakhsoliani E, Stanciu L, Bartlett N, Edwards M, Walton R, Mallia P, Hunt TM, Hunt TL, Hunt DG, Westwick J, Edwards M, Kon OM, Jackson DJ, Johnston SL (2017) A Comprehensive evaluation of nasal and bronchial cytokines and chemokines following experimental rhinovirus infection in allergic asthma: increased interferons (IFN-gamma and IFN-lambda) and type 2 inflammation (IL-5 and IL-13). EBioMedicine 19:128–138PubMedCentral
68.
Zurück zum Zitat Sykes A, Macintyre J, Edwards MR, Del Rosario A, Haas J, Gielen V, Kon OM, McHale M, Johnston SL (2014) Rhinovirus-induced interferon production is not deficient in well controlled asthma. Thorax 69(3):240–246 Sykes A, Macintyre J, Edwards MR, Del Rosario A, Haas J, Gielen V, Kon OM, McHale M, Johnston SL (2014) Rhinovirus-induced interferon production is not deficient in well controlled asthma. Thorax 69(3):240–246
69.
Zurück zum Zitat Bielor C, Sopel N, Maier A, Blau A, Sharma H, Vuorinen T, Kross B, Mittler S, Graser A, Mousset S, Melichar VO, Kiefer A, Zimmermann T, Springel R, Holzinger C, Trump S, Taka S, Papadopoulos NG, Weiss ST, Finotto S (2017) Role of TGF-beta in anti-rhinovirus immune responses in asthmatic patients. J Allergy Clin Immunol 140(1):283–286 e10PubMedPubMedCentral Bielor C, Sopel N, Maier A, Blau A, Sharma H, Vuorinen T, Kross B, Mittler S, Graser A, Mousset S, Melichar VO, Kiefer A, Zimmermann T, Springel R, Holzinger C, Trump S, Taka S, Papadopoulos NG, Weiss ST, Finotto S (2017) Role of TGF-beta in anti-rhinovirus immune responses in asthmatic patients. J Allergy Clin Immunol 140(1):283–286 e10PubMedPubMedCentral
70.
Zurück zum Zitat Usui T, Nishikomori R, Kitani A, Strober W (2003) GATA-3 suppresses Th1 development by downregulation of Stat4 and not through effects on IL-12Rbeta2 chain or T-bet. Immunity 18(3):415–428PubMed Usui T, Nishikomori R, Kitani A, Strober W (2003) GATA-3 suppresses Th1 development by downregulation of Stat4 and not through effects on IL-12Rbeta2 chain or T-bet. Immunity 18(3):415–428PubMed
71.
Zurück zum Zitat Zhu J, Jankovic D, Oler AJ, Wei G, Sharma S, Hu G, Guo L, Yagi R, Yamane H, Punkosdy G, Feigenbaum L, Zhao K, Paul WE (2012) The transcription factor T-bet is induced by multiple pathways and prevents an endogenous Th2 cell program during Th1 cell responses. Immunity 37(4):660–673PubMedPubMedCentral Zhu J, Jankovic D, Oler AJ, Wei G, Sharma S, Hu G, Guo L, Yagi R, Yamane H, Punkosdy G, Feigenbaum L, Zhao K, Paul WE (2012) The transcription factor T-bet is induced by multiple pathways and prevents an endogenous Th2 cell program during Th1 cell responses. Immunity 37(4):660–673PubMedPubMedCentral
72.
Zurück zum Zitat Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH (2000) A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100(6):655–669PubMed Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH (2000) A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100(6):655–669PubMed
73.
Zurück zum Zitat Neurath MF, Weigmann B, Finotto S, Glickman J, Nieuwenhuis E, Iijima H, Mizoguchi A, Mizoguchi E, Mudter J, Galle PR, Bhan A, Autschbach F, Sullivan BM, Szabo SJ, Glimcher LH, Blumberg RS (2002) The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn’s disease. J Exp Med 195(9):1129–1143PubMedPubMedCentral Neurath MF, Weigmann B, Finotto S, Glickman J, Nieuwenhuis E, Iijima H, Mizoguchi A, Mizoguchi E, Mudter J, Galle PR, Bhan A, Autschbach F, Sullivan BM, Szabo SJ, Glimcher LH, Blumberg RS (2002) The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn’s disease. J Exp Med 195(9):1129–1143PubMedPubMedCentral
74.
Zurück zum Zitat Finotto S, Neurath MF, Glickman JN, Qin S, Lehr HA, Green FH, Ackerman K, Haley K, Galle PR, Szabo SJ, Drazen JM, De Sanctis GT, Glimcher LH (2002) Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet. Science 295(5553):336–338PubMed Finotto S, Neurath MF, Glickman JN, Qin S, Lehr HA, Green FH, Ackerman K, Haley K, Galle PR, Szabo SJ, Drazen JM, De Sanctis GT, Glimcher LH (2002) Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet. Science 295(5553):336–338PubMed
75.
Zurück zum Zitat Liu X, Li S, Jin J, Zhu T, Xu K, Liu C, Zeng Y, Mao R, Wang X, Chen Z (2019) Preventative tracheal administration of interleukin-27 attenuates allergic asthma by improving the lung Th1 microenvironment. J Cell Physiol 234(5):6642–6653PubMed Liu X, Li S, Jin J, Zhu T, Xu K, Liu C, Zeng Y, Mao R, Wang X, Chen Z (2019) Preventative tracheal administration of interleukin-27 attenuates allergic asthma by improving the lung Th1 microenvironment. J Cell Physiol 234(5):6642–6653PubMed
76.
Zurück zum Zitat Joerger M, Finn SP, Cuffe S, Byrne AT, Gray SG (2016) The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy? Expert Opin Ther Targets 20(11):1339–1356PubMed Joerger M, Finn SP, Cuffe S, Byrne AT, Gray SG (2016) The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy? Expert Opin Ther Targets 20(11):1339–1356PubMed
77.
Zurück zum Zitat Reppert S, Boross I, Koslowski M, Tureci O, Koch S, Lehr HA, Finotto S (2011) A role for T-bet-mediated tumour immune surveillance in anti-IL-17A treatment of lung cancer. Nat Commun 2:600PubMed Reppert S, Boross I, Koslowski M, Tureci O, Koch S, Lehr HA, Finotto S (2011) A role for T-bet-mediated tumour immune surveillance in anti-IL-17A treatment of lung cancer. Nat Commun 2:600PubMed
78.
Zurück zum Zitat Xu L, Sun WJ, Jia AJ, Qiu LL, Xiao B, Mu L, Li JM, Zhang XF, Wei Y, Peng C, Zhang DS, Xiang XD (2018) MBD2 regulates differentiation and function of Th17 cells in neutrophils- dominant asthma via HIF-1alpha. J Inflamm 15:15 Xu L, Sun WJ, Jia AJ, Qiu LL, Xiao B, Mu L, Li JM, Zhang XF, Wei Y, Peng C, Zhang DS, Xiang XD (2018) MBD2 regulates differentiation and function of Th17 cells in neutrophils- dominant asthma via HIF-1alpha. J Inflamm 15:15
79.
Zurück zum Zitat Vroman H, Bergen IM, van Hulst JAC, van Nimwegen M, van Uden D, Schuijs MJ, Pillai SY, van Loo G, Hammad H, Lambrecht BN, Hendriks RW, Kool M (2018) TNF-alpha-induced protein 3 levels in lung dendritic cells instruct TH2 or TH17 cell differentiation in eosinophilic or neutrophilic asthma. 141(5):1620–J Allergy Clin Immunol, 1633 e12 Vroman H, Bergen IM, van Hulst JAC, van Nimwegen M, van Uden D, Schuijs MJ, Pillai SY, van Loo G, Hammad H, Lambrecht BN, Hendriks RW, Kool M (2018) TNF-alpha-induced protein 3 levels in lung dendritic cells instruct TH2 or TH17 cell differentiation in eosinophilic or neutrophilic asthma. 141(5):1620–J Allergy Clin Immunol, 1633 e12
80.
Zurück zum Zitat Wang L, Wan H, Tang W, Ni Y, Hou X, Pan L, Song Y, Shi G (2018) Critical roles of adenosine A2A receptor in regulating the balance of Treg/Th17 cells in allergic asthma. Clin Respir J 12(1):149–157PubMed Wang L, Wan H, Tang W, Ni Y, Hou X, Pan L, Song Y, Shi G (2018) Critical roles of adenosine A2A receptor in regulating the balance of Treg/Th17 cells in allergic asthma. Clin Respir J 12(1):149–157PubMed
81.
Zurück zum Zitat Guan Q, Yang B, Warrington RJ, Mink S, Kalicinsky C, Becker AB, Simons E, Peng Z (2019) Myeloid-derived suppressor cells: roles and relations with Th2, Th17, and Treg cells in asthma. Allergy Guan Q, Yang B, Warrington RJ, Mink S, Kalicinsky C, Becker AB, Simons E, Peng Z (2019) Myeloid-derived suppressor cells: roles and relations with Th2, Th17, and Treg cells in asthma. Allergy
82.
Zurück zum Zitat Ramakrishnan RK, Al Heialy S, Hamid Q (2019) Role of IL-17 in asthma pathogenesis and its implications for the clinic. Expert Rev Respir Med:1–12 Ramakrishnan RK, Al Heialy S, Hamid Q (2019) Role of IL-17 in asthma pathogenesis and its implications for the clinic. Expert Rev Respir Med:1–12
83.
Zurück zum Zitat Quan-San Z, Xiaohong X, Ying L, Zhaojia S (2019) Role of Th17-cell related cytokines in geriatric asthma. J Int Med Res 47(2):580–590PubMed Quan-San Z, Xiaohong X, Ying L, Zhaojia S (2019) Role of Th17-cell related cytokines in geriatric asthma. J Int Med Res 47(2):580–590PubMed
84.
Zurück zum Zitat Zou XL, Chen ZG, Zhang TT, Feng DY, Li HT, Yang HL (2018) Th17/Treg homeostasis, but not Th1/Th2 homeostasis, is implicated in exacerbation of human bronchial asthma. Ther Clin Risk Manag 14:1627–1636PubMedPubMedCentral Zou XL, Chen ZG, Zhang TT, Feng DY, Li HT, Yang HL (2018) Th17/Treg homeostasis, but not Th1/Th2 homeostasis, is implicated in exacerbation of human bronchial asthma. Ther Clin Risk Manag 14:1627–1636PubMedPubMedCentral
85.
Zurück zum Zitat Massague J, Attisano L, Wrana JL (1994) The TGF-beta family and its composite receptors. Trends Cell Biol 4(5):172–178PubMed Massague J, Attisano L, Wrana JL (1994) The TGF-beta family and its composite receptors. Trends Cell Biol 4(5):172–178PubMed
86.
Zurück zum Zitat Chaudhry A, Rudra D, Treuting P, Samstein RM, Liang Y, Kas A, Rudensky AY (2009) CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. Science 326(5955):986–991PubMedPubMedCentral Chaudhry A, Rudra D, Treuting P, Samstein RM, Liang Y, Kas A, Rudensky AY (2009) CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. Science 326(5955):986–991PubMedPubMedCentral
87.
Zurück zum Zitat DeVries A, Vercelli D (2018) Of pleiotropy and trajectories: Does the TGF-beta pathway link childhood asthma and chronic obstructive pulmonary disease? J Allergy Clin Immunol 141(6):1992–1996PubMedPubMedCentral DeVries A, Vercelli D (2018) Of pleiotropy and trajectories: Does the TGF-beta pathway link childhood asthma and chronic obstructive pulmonary disease? J Allergy Clin Immunol 141(6):1992–1996PubMedPubMedCentral
88.
Zurück zum Zitat Branchett WJ, Stolting H, Oliver RA, Walker SA, Puttur F, Gregory LG, Gabrysova L, Wilson MS, O'Garra A, Lloyd CM (2019) A T cell-myeloid IL-10 axis regulates pathogenic IFN-gamma-dependent immunity in a mouse model of type 2-low asthma. J Allergy Clin Immunol Branchett WJ, Stolting H, Oliver RA, Walker SA, Puttur F, Gregory LG, Gabrysova L, Wilson MS, O'Garra A, Lloyd CM (2019) A T cell-myeloid IL-10 axis regulates pathogenic IFN-gamma-dependent immunity in a mouse model of type 2-low asthma. J Allergy Clin Immunol
89.
Zurück zum Zitat Zonoobi E, Saeedfar K, Pourdowlat G, Masjedi MR, Behmanesh M (2018) The study of IL-10 and IL-17A genes expression in patients with different stages of asthma: a case-control study. Tanaffos 17(3):146–154PubMedPubMedCentral Zonoobi E, Saeedfar K, Pourdowlat G, Masjedi MR, Behmanesh M (2018) The study of IL-10 and IL-17A genes expression in patients with different stages of asthma: a case-control study. Tanaffos 17(3):146–154PubMedPubMedCentral
90.
Zurück zum Zitat Paw M, Wnuk D, Kadziolka D, Sek A, Lasota S, Czyz J, Madeja Z, Michalik M (2018) Fenofibrate reduces the asthma-related fibroblast-to-myofibroblast transition by TGF-beta/Smad2/3 signaling attenuation and connexin 43-dependent phenotype destabilization. Int J Mol Sci 19(9)PubMedCentral Paw M, Wnuk D, Kadziolka D, Sek A, Lasota S, Czyz J, Madeja Z, Michalik M (2018) Fenofibrate reduces the asthma-related fibroblast-to-myofibroblast transition by TGF-beta/Smad2/3 signaling attenuation and connexin 43-dependent phenotype destabilization. Int J Mol Sci 19(9)PubMedCentral
91.
Zurück zum Zitat Chen S, Han Y, Chen H, Wu J, Zhang M (2018) Bcl11b regulates IL-17 through the TGF-beta/Smad pathway in HDM-induced asthma. Allergy, Asthma Immunol Res 10(5):543–554 Chen S, Han Y, Chen H, Wu J, Zhang M (2018) Bcl11b regulates IL-17 through the TGF-beta/Smad pathway in HDM-induced asthma. Allergy, Asthma Immunol Res 10(5):543–554
92.
Zurück zum Zitat Haspeslagh E, Vanheerswynghels M, Deswarte K, Van Moorleghem J, Jacquet A, Lambrecht BN, Hammad H (2019) Prophylactic allergen immunotherapy with Der p 2 prevents murine asthma by regulating lung GM-CSF. J Allergy Clin Immunol 143(6):2307–2311 e5PubMed Haspeslagh E, Vanheerswynghels M, Deswarte K, Van Moorleghem J, Jacquet A, Lambrecht BN, Hammad H (2019) Prophylactic allergen immunotherapy with Der p 2 prevents murine asthma by regulating lung GM-CSF. J Allergy Clin Immunol 143(6):2307–2311 e5PubMed
93.
Zurück zum Zitat Bohm L, Maxeiner J, Meyer-Martin H, Reuter S, Finotto S, Klein M, Schild H, Schmitt E, Bopp T, Taube C (2015) IL-10 and regulatory T cells cooperate in allergen-specific immunotherapy to ameliorate allergic asthma. J Immunol 194(3):887–897PubMed Bohm L, Maxeiner J, Meyer-Martin H, Reuter S, Finotto S, Klein M, Schild H, Schmitt E, Bopp T, Taube C (2015) IL-10 and regulatory T cells cooperate in allergen-specific immunotherapy to ameliorate allergic asthma. J Immunol 194(3):887–897PubMed
94.
Zurück zum Zitat Asamoah F, Kakourou A, Dhami S, Lau S, Agache I, Muraro A, Roberts G, Akdis C, Bonini M, Cavkaytar O, Flood B, Izuhara K, Jutel M, Kalayci O, Pfaar O, Sheikh A (2017) Allergen immunotherapy for allergic asthma: a systematic overview of systematic reviews. Clin Transl Allergy 7:25PubMedPubMedCentral Asamoah F, Kakourou A, Dhami S, Lau S, Agache I, Muraro A, Roberts G, Akdis C, Bonini M, Cavkaytar O, Flood B, Izuhara K, Jutel M, Kalayci O, Pfaar O, Sheikh A (2017) Allergen immunotherapy for allergic asthma: a systematic overview of systematic reviews. Clin Transl Allergy 7:25PubMedPubMedCentral
95.
Zurück zum Zitat Dhami S, Kakourou A, Asamoah F, Agache I, Lau S, Jutel M, Muraro A, Roberts G, Akdis CA, Bonini M, Cavkaytar O, Flood B, Gajdanowicz P, Izuhara K, Kalayci O, Mosges R, Palomares O, Pfaar O, Smolinska S, Sokolowska M, Asaria M, Netuveli G, Zaman H, Akhlaq A, Sheikh A (2017) Allergen immunotherapy for allergic asthma: a systematic review and meta-analysis. Allergy 72(12):1825–1848PubMed Dhami S, Kakourou A, Asamoah F, Agache I, Lau S, Jutel M, Muraro A, Roberts G, Akdis CA, Bonini M, Cavkaytar O, Flood B, Gajdanowicz P, Izuhara K, Kalayci O, Mosges R, Palomares O, Pfaar O, Smolinska S, Sokolowska M, Asaria M, Netuveli G, Zaman H, Akhlaq A, Sheikh A (2017) Allergen immunotherapy for allergic asthma: a systematic review and meta-analysis. Allergy 72(12):1825–1848PubMed
96.
Zurück zum Zitat MacDonald KM, Kavati A, Ortiz B, Alhossan A, Lee CS, Abraham I (2019) Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018. Expert Rev Clin Immunol 15(5):553–569PubMed MacDonald KM, Kavati A, Ortiz B, Alhossan A, Lee CS, Abraham I (2019) Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018. Expert Rev Clin Immunol 15(5):553–569PubMed
97.
Zurück zum Zitat Nishima S, Kozawa M, Milligan KL, Papadopoulos NG (2019) Omalizumab and unmet needs in severe asthma and allergic comorbidities in Japanese children. Asia Pac Allergy 9(1):e7PubMedCentral Nishima S, Kozawa M, Milligan KL, Papadopoulos NG (2019) Omalizumab and unmet needs in severe asthma and allergic comorbidities in Japanese children. Asia Pac Allergy 9(1):e7PubMedCentral
98.
Zurück zum Zitat Deschildre A, Roussel J, Drumez E, Abou-Taam R, Rames C, Le Roux P, Pouessel G, Scalbert M, Bonnel C, Mitha S, Boileau S, Mordacq C, Thumerelle C, Labreuche J, Lejeune S, Marguet C (2019) Omalizumab discontinuation in children with severe allergic asthma: an observational real-life study. Allergy 74(5):999–1003PubMed Deschildre A, Roussel J, Drumez E, Abou-Taam R, Rames C, Le Roux P, Pouessel G, Scalbert M, Bonnel C, Mitha S, Boileau S, Mordacq C, Thumerelle C, Labreuche J, Lejeune S, Marguet C (2019) Omalizumab discontinuation in children with severe allergic asthma: an observational real-life study. Allergy 74(5):999–1003PubMed
99.
Zurück zum Zitat Fiocchi A, Artesani MC, Riccardi C, Mennini M, Pecora V, Fierro V, Calandrelli V, Dahdah L, Valluzzi RL (2019) Impact of omalizumab on food allergy in patients treated for asthma: a real-life study. J Allergy Clin Immunol Pract 7(6):1901–1909 e5PubMed Fiocchi A, Artesani MC, Riccardi C, Mennini M, Pecora V, Fierro V, Calandrelli V, Dahdah L, Valluzzi RL (2019) Impact of omalizumab on food allergy in patients treated for asthma: a real-life study. J Allergy Clin Immunol Pract 7(6):1901–1909 e5PubMed
100.
Zurück zum Zitat Weir E, Paton J (2019) Mepolizumab in adolescents with severe eosinophilic asthma not eligible for omalizumab: one center’s early clinical experience. J Asthma 22:1–4 Weir E, Paton J (2019) Mepolizumab in adolescents with severe eosinophilic asthma not eligible for omalizumab: one center’s early clinical experience. J Asthma 22:1–4
101.
Zurück zum Zitat Davila Gonzalez I, Moreno Benitez F, Quirce S (2019) Benralizumab: a new approach for the treatment of severe eosinophilic asthma. J Investig Allergol Clin Immunol 29(2):84–93PubMed Davila Gonzalez I, Moreno Benitez F, Quirce S (2019) Benralizumab: a new approach for the treatment of severe eosinophilic asthma. J Investig Allergol Clin Immunol 29(2):84–93PubMed
102.
Zurück zum Zitat Chupp G, Lugogo NL, Kline JN, Ferguson GT, Hirsch I, Goldman M, Zangrilli JG, Trudo F (2019) Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthma. Ann Allergy Asthma Immunol 122(5):478–485PubMed Chupp G, Lugogo NL, Kline JN, Ferguson GT, Hirsch I, Goldman M, Zangrilli JG, Trudo F (2019) Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthma. Ann Allergy Asthma Immunol 122(5):478–485PubMed
103.
Zurück zum Zitat Minami D, Kayatani H, Sato K, Fujiwara K, Shibayama T (2019) Effectiveness of benralizumab for allergic and eosinophilic predominant asthma following negative initial results with omalizumab. Respirol Case Rep 7(1):e00388PubMed Minami D, Kayatani H, Sato K, Fujiwara K, Shibayama T (2019) Effectiveness of benralizumab for allergic and eosinophilic predominant asthma following negative initial results with omalizumab. Respirol Case Rep 7(1):e00388PubMed
104.
Zurück zum Zitat Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, Olsson RF, Martin UJ, Goldman M, B.s. investigators (2019) Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med 7(1):46–59PubMed Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, Olsson RF, Martin UJ, Goldman M, B.s. investigators (2019) Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med 7(1):46–59PubMed
105.
Zurück zum Zitat Zayed Y, Kheiri B, Banifadel M, Hicks M, Aburahma A, Hamid K, Bachuwa G, Chandran A (2018) Dupilumab safety and efficacy in uncontrolled asthma: a systematic review and meta-analysis of randomized clinical trials. J Asthma 1:1–10 Zayed Y, Kheiri B, Banifadel M, Hicks M, Aburahma A, Hamid K, Bachuwa G, Chandran A (2018) Dupilumab safety and efficacy in uncontrolled asthma: a systematic review and meta-analysis of randomized clinical trials. J Asthma 1:1–10
106.
Zurück zum Zitat Corren J, Castro M, Chanez P, Fabbri L, Joish VN, Amin N, Graham NMH, Mastey V, Abbe A, Taniou C, Mahajan P, Teper A, Pirozzi G, Eckert L (2019) Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma. Ann Allergy Asthma Immunol 122(1):41–49 e2 Corren J, Castro M, Chanez P, Fabbri L, Joish VN, Amin N, Graham NMH, Mastey V, Abbe A, Taniou C, Mahajan P, Teper A, Pirozzi G, Eckert L (2019) Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma. Ann Allergy Asthma Immunol 122(1):41–49 e2
107.
Zurück zum Zitat Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, Zhu H, Hamilton JD, Swanson BN, Khan A, Chao J, Staudinger H, Pirozzi G, Antoni C, Amin N, Ruddy M, Akinlade B, Graham NMH, Stahl N, Yancopoulos GD, Teper A (2018) Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 378(26):2475–2485 Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, Zhu H, Hamilton JD, Swanson BN, Khan A, Chao J, Staudinger H, Pirozzi G, Antoni C, Amin N, Ruddy M, Akinlade B, Graham NMH, Stahl N, Yancopoulos GD, Teper A (2018) Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 378(26):2475–2485
108.
Zurück zum Zitat Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, Katelaris C, Tohda Y, Zhang B, Staudinger H, Pirozzi G, Amin N, Ruddy M, Akinlade B, Khan A, Chao J, Martincova R, Graham NMH, Hamilton JD, Swanson BN, Stahl N, Yancopoulos GD, Teper A (2018) Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 378(26):2486–2496PubMed Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, Katelaris C, Tohda Y, Zhang B, Staudinger H, Pirozzi G, Amin N, Ruddy M, Akinlade B, Khan A, Chao J, Martincova R, Graham NMH, Hamilton JD, Swanson BN, Stahl N, Yancopoulos GD, Teper A (2018) Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 378(26):2486–2496PubMed
109.
Zurück zum Zitat Busse WW, Maspero JF, Rabe KF, Papi A, Wenzel SE, Ford LB, Pavord ID, Zhang B, Staudinger H, Pirozzi G, Amin N, Akinlade B, Eckert L, Chao J, Graham NMH, Teper A (2018) Liberty asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate Dupilumab efficacy/safety in patients with uncontrolled, moderate-to-severe asthma. Adv Ther 35(5):737–748PubMedPubMedCentral Busse WW, Maspero JF, Rabe KF, Papi A, Wenzel SE, Ford LB, Pavord ID, Zhang B, Staudinger H, Pirozzi G, Amin N, Akinlade B, Eckert L, Chao J, Graham NMH, Teper A (2018) Liberty asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate Dupilumab efficacy/safety in patients with uncontrolled, moderate-to-severe asthma. Adv Ther 35(5):737–748PubMedPubMedCentral
110.
Zurück zum Zitat Weinstein SF, Katial R, Jayawardena S, Pirozzi G, Staudinger H, Eckert L, Joish VN, Amin N, Maroni J, Rowe P, Graham NMH, Teper A (2018) Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma. J Allergy Clin Immunol 142(1):171–177 e1PubMed Weinstein SF, Katial R, Jayawardena S, Pirozzi G, Staudinger H, Eckert L, Joish VN, Amin N, Maroni J, Rowe P, Graham NMH, Teper A (2018) Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma. J Allergy Clin Immunol 142(1):171–177 e1PubMed
Metadaten
Titel
Resolution of allergic asthma
verfasst von
Susetta Finotto
Publikationsdatum
08.11.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Seminars in Immunopathology / Ausgabe 6/2019
Print ISSN: 1863-2297
Elektronische ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-019-00770-3

Weitere Artikel der Ausgabe 6/2019

Seminars in Immunopathology 6/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.